Below are the most recent publications written about "Cell Growth Processes" by people in Profiles.
-
Nikbakht N, Tiago M, Erkes DA, Chervoneva I, Aplin AE. BET Inhibition Modifies Melanoma Infiltrating T Cells and Enhances Response to PD-L1 Blockade. J Invest Dermatol. 2019 07; 139(7):1612-1615.
-
Lapadula D, Farias E, Randolph CE, Purwin TJ, McGrath D, Charpentier TH, Zhang L, Wu S, Terai M, Sato T, Tall GG, Zhou N, Wedegaertner PB, Aplin AE, Aguirre-Ghiso J, Benovic JL. Effects of Oncogenic Gaq and Ga11 Inhibition by FR900359 in Uveal Melanoma. Mol Cancer Res. 2019 04; 17(4):963-973.
-
Lertsuwan K, Peters W, Johnson L, Lertsuwan J, Marwa I, Sikes RA. Purinergic Receptor Expression and Cellular Responses to Purinergic Agonists in Human Prostate Cancer Cells. Anticancer Res. 2017 02; 37(2):529-537.
-
Alexander ET, Minton AR, Peters MC, van Ryn J, Gilmour SK. Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment. Oncotarget. 2016 Dec 20; 7(51):85291-85305.
-
Han N, Yuan X, Wu H, Xu H, Chu Q, Guo M, Yu S, Chen Y, Wu K. DACH1 inhibits lung adenocarcinoma invasion and tumor growth by repressing CXCL5 signaling. Oncotarget. 2015 Mar 20; 6(8):5877-88.
-
Wang T, Guo S, Liu Z, Wu L, Li M, Yang J, Chen R, Liu X, Xu H, Cai S, Chen H, Li W, Xu S, Wang L, Hu Z, Zhuang Q, Wang L, Wu K, Liu J, Ye Z, Ji JY, Wang C, Chen K. CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling. Oncotarget. 2014 Nov 15; 5(21):10293-306.
-
Chu Q, Han N, Yuan X, Nie X, Wu H, Chen Y, Guo M, Yu S, Wu K. DACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells. J Hematol Oncol. 2014 Oct 17; 7:73.
-
Kugel CH, Hartsough EJ, Davies MA, Setiady YY, Aplin AE. Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor. Cancer Res. 2014 Aug 01; 74(15):4122-32.
-
Quatromoni JG, Predina JD, Bhojnagarwala P, Judy RP, Jiang J, De Jesus EM, Kapoor V, Cheng G, Okusanya OT, Eruslanov E, Singhal S. Adenoviral-based immunotherapy provides local disease control in an orthotopic murine model of esophageal cancer. J Immunother. 2014 Jun; 37(5):283-92.
-
Yu Z, Xu Z, Disante G, Wright J, Wang M, Li Y, Zhao Q, Ren T, Ju X, Gutman E, Wang G, Addya S, Li T, Xiang Z, Wang C, Yang X, Yang X, Pestell R. miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1. Oncotarget. 2014 Feb 28; 5(4):1083-90.